Venegas J, Onur O, Kang S, Hitomi M, Eng C
Endocr Relat Cancer. 2025; 32(4).
PMID: 39970536
PMC: 11906015.
DOI: 10.1530/ERC-24-0216.
Cai F, Liu Z, Zou J, Liu Y, Tang W, Zhou L
Heliyon. 2024; 10(16):e36190.
PMID: 39224372
PMC: 11367504.
DOI: 10.1016/j.heliyon.2024.e36190.
Fasano C, Lepore Signorile M, De Marco K, Forte G, Disciglio V, Sanese P
Cells. 2024; 13(16.
PMID: 39195204
PMC: 11352798.
DOI: 10.3390/cells13161314.
He S, Zhu Y, Chauhan S, Tavakol D, Lee J, Berris R
bioRxiv. 2024; .
PMID: 38328122
PMC: 10849631.
DOI: 10.1101/2024.01.26.577324.
El Nachef L, Berthel E, Ferlazzo M, Le Reun E, Al-Choboq J, Restier-Verlet J
Cancers (Basel). 2022; 14(24).
PMID: 36551628
PMC: 9776478.
DOI: 10.3390/cancers14246141.
Overgrowth syndromes and new therapies.
Eng W, Hammill A, Adams D
Semin Pediatr Surg. 2020; 29(5):150974.
PMID: 33069285
PMC: 11126324.
DOI: 10.1016/j.sempedsurg.2020.150974.
Proteus syndrome: a case report and a case study review in China.
Zhang X, Li C, He Y, Zhang S, Cai Y
Dermatol Reports. 2014; 2(1):e3.
PMID: 25386239
PMC: 4211478.
DOI: 10.4081/dr.2010.e3.
Germline PTEN, SDHB-D, and KLLN alterations in endometrial cancer patients with Cowden and Cowden-like syndromes: an international, multicenter, prospective study.
Mahdi H, Mester J, Nizialek E, Ngeow J, Michener C, Eng C
Cancer. 2014; 121(5):688-96.
PMID: 25376524
PMC: 4339629.
DOI: 10.1002/cncr.29106.
Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.
Ngeow J, Stanuch K, Mester J, Barnholtz-Sloan J, Eng C
J Clin Oncol. 2014; 32(17):1818-24.
PMID: 24778394
PMC: 4039869.
DOI: 10.1200/JCO.2013.53.6656.
Germline alterations in RASAL1 in Cowden syndrome patients presenting with follicular thyroid cancer and in individuals with apparently sporadic epithelial thyroid cancer.
Ngeow J, Ni Y, Tohme R, Song Chen F, Bebek G, Eng C
J Clin Endocrinol Metab. 2014; 99(7):E1316-21.
PMID: 24712574
PMC: 5393485.
DOI: 10.1210/jc.2014-1225.
Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.
Ngeow J, He X, Mester J, Lei J, Romigh T, Orloff M
J Clin Endocrinol Metab. 2012; 97(12):E2320-7.
PMID: 23066114
PMC: 3513537.
DOI: 10.1210/jc.2012-2944.
Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations.
Ngeow J, Mester J, Rybicki L, Ni Y, Milas M, Eng C
J Clin Endocrinol Metab. 2011; 96(12):E2063-71.
PMID: 21956414
PMC: 3232626.
DOI: 10.1210/jc.2011-1616.
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z, Doondeea J, Gholami A, Janning M, Lemeer S, Kramer K
Mol Cell Proteomics. 2011; 10(12):M111.011635.
PMID: 21955398
PMC: 3237086.
DOI: 10.1074/mcp.M111.011635.
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.
Tan M, Mester J, Peterson C, Yang Y, Chen J, Rybicki L
Am J Hum Genet. 2011; 88(1):42-56.
PMID: 21194675
PMC: 3014373.
DOI: 10.1016/j.ajhg.2010.11.013.
Nuclear PTEN levels and G2 progression in melanoma cells.
Jacob A, Romigh T, Waite K, Eng C
Melanoma Res. 2009; 19(4):203-10.
PMID: 19478684
PMC: 2750820.
DOI: 10.1097/CMR.0b013e32832ccd6e.
Role of APC and DNA mismatch repair genes in the development of colorectal cancers.
Narayan S, Roy D
Mol Cancer. 2003; 2:41.
PMID: 14672538
PMC: 317355.
DOI: 10.1186/1476-4598-2-41.
